Status:
COMPLETED
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
Lead Sponsor:
Bayer
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The study drug, radium-223, gives off radiation that helps to kill cancer cells in the prostate. It is already available for patients to receive as a treatment for prostate cancer that has not respond...
Eligibility Criteria
Inclusion
- Male adult patients (\> 18 years)
- Label Xofigo
- Signed informed consent
- No participation in an investigational program with interventions outside of routine clinical practice.
- Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice, as treatment option for mCRPC either as first line (naïve), second line (after progression during treatment with enzalutamide or abiraterone) or third line (post-Docetaxel).
Exclusion
- Patients with contraindications to the use of Radium-223 according to the local label.
- Patients and who refused to sign the informed consent form.
Key Trial Info
Start Date :
April 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 21 2022
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04681144
Start Date
April 8 2021
End Date
November 21 2022
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Colombia